



Australian Government
Department of Health
 Therapeutic Goods Administration

Public Summary

Summary for ARTG Entry:	326211	Mega B Complex
ARTG entry for	Medicine Listed	
Sponsor	Herbs of Gold Pty Ltd	
Postal Address	PO Box 3143, KIRRAWEE, NSW, 2232 Australia	
ARTG Start Date	13/11/2019	
Product Category	Medicine	
Status	Active	
Approval Area	Listed Medicines	

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1 . Mega B Complex

Product Type	Effective Date
Single Medicine Product	13/11/2019

Permitted Indications

- Helps convert (state food) into energy
- Maintain/support energy production
- Maintain/support general health and wellbeing
- Aid/assist healthy red blood cell production
- Maintain/support red blood cell health
- Maintain/support blood health
- Helps maintain/support haemoglobin formation/synthesis
- Maintain/support cardiovascular system health
- Aid/assist/helps glucose/sugar/carbohydrate metabolism
- Helps prevent dietary (state vitamin/mineral/nutrient) deficiency
- Aid/assist/helps metabolism of (state vitamin/mineral/nutrient)
- Support healthy stress response in the body
- Maintain/support cognitive function/mental function
- Maintain/support brain function
- Maintain/support brain health
- Aid/assist/helps synthesis of neurotransmitters
- Maintain/support nervous system health
- Maintain/support nervous system function
- Maintains/support healthy foetal development

Public Summary



Australian Government
Department of Health
 Therapeutic Goods Administration

Maintain/support skin health

Indication Requirements

Product presentation must not imply or refer to lowering or raising blood sugar/glucose levels from outside of the normal healthy range.
 Product presentation must not imply or refer to mental illnesses, disorders or conditions.
 Product presentation must not imply or refer to serious cardiovascular conditions.
 Label statement: [Vitamins/minerals/nutrients/dietary supplements] can only be of assistance if dietary intake is inadequate OR [Vitamins/minerals/nutrients/dietary supplements] should not replace a balanced diet (or words to that effect).
 If directed to women, Label statement: Advise your doctor of any medicine you take during pregnancy, particularly in your first trimester.
 If product is indicated for weight loss, label statement: When used in conjunction with a program of reduced intake of dietary calories and increased physical activity.
 If product is indicated for supplementation, Label statement: [Vitamins/minerals/nutrients/dietary supplements] can only be of assistance if dietary intake is inadequate OR [Vitamins/minerals/nutrients/dietary supplements] should not replace a balanced diet (or words to that effect).

Standard Indications

No Standard Indications included on Record

Specific Indications

No Specific Indications included on Record

Warnings

WARNING - Stop taking this medication if you experience tingling, burning or numbness and see your healthcare practitioner as soon as possible. [Contains vitamin B6].

Additional Product information

Pack Size/Poison information

Pack Size	Poison Schedule
------------------	------------------------

Components

1 . Formulation 1

Dosage Form	Capsule, hard
Route of Administration	Oral

Visual Identification

Active Ingredients

Biotin	100 microgram
calcium folinate	537.5 microgram
Equivalent: folic acid	400 microgram
calcium pantothenate	75 mg
Equivalent: pantothenic acid	68.18 mg
choline bitartrate	50 mg
cyanocobalamin	500 microgram
inositol	50 mg
nicotinamide	100 mg
nicotinic acid	10 mg
pyridoxine hydrochloride	100 mg
Equivalent: pyridoxine	82.27 mg
riboflavine	100 mg
thiamine hydrochloride	100 mg
Equivalent: thiamine	89.19 mg

Other Ingredients (Excipients)

colloidal anhydrous silica
disodium edetate
Flavour
gellan gum
hypromellose

Public Summary



Australian Government

Department of Health
Therapeutic Goods Administration

potable water

potassium acetate

silicon dioxide

stearic acid

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary